Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Cash from Financing Activities (2023 - 2025)

Mereo BioPharma (MREO) has disclosed Cash from Financing Activities for 3 consecutive years, with -$134000.0 as the latest value for Q2 2025.

  • On a quarterly basis, Cash from Financing Activities fell 100.29% to -$134000.0 in Q2 2025 year-over-year; TTM through Sep 2025 was $248000.0, a 99.46% decrease, with the full-year FY2024 number at $46.1 million, up 478.79% from a year prior.
  • Cash from Financing Activities was -$134000.0 for Q2 2025 at Mereo BioPharma, down from $422000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $46.8 million in Q2 2024 to a low of -$594000.0 in Q3 2024.
  • A 3-year average of $9.1 million and a median of $191000.0 in 2024 define the central range for Cash from Financing Activities.
  • Peak YoY movement for Cash from Financing Activities: plummeted 107.51% in 2024, then crashed 100.29% in 2025.
  • Mereo BioPharma's Cash from Financing Activities stood at $7.9 million in 2023, then plummeted by 100.51% to -$40000.0 in 2024, then tumbled by 235.0% to -$134000.0 in 2025.
  • Per Business Quant, the three most recent readings for MREO's Cash from Financing Activities are -$134000.0 (Q2 2025), $422000.0 (Q1 2025), and -$40000.0 (Q4 2024).